喉癌组织中微小RNA-129-2基因甲基化程度的研究

Methylation of MicroRNA-129-2 in Laryngeal Cancer

目的研究喉癌肿瘤组织中微小RNA-129-2基因(MiR-129-2)的甲基化程度及其与患者临床分级和癌组织病理分化程度的关系。方法应用Methyl-ProfilerTM DNA甲基化PCR系统对12例喉癌肿瘤组织和6例癌旁组织进行甲基化分析。结果喉癌组织中MiR-129-2高甲基化率为66.7%(8/12),癌旁组织中MiR-129-2高甲基化率为0(0/6),两组比较差异有统计学意义(P<0.05)。喉癌患者临床分级与MiR-129-2高甲基化率差异无统计学意义(P>0.0 5)。病理分化程度与MiR-1 2 9-2高甲基化率差异无统计学意义(P>0.0 5)。结论 MiR-1 2 9-2基因在喉癌组织中甲基化水平升高,MiR-1 2 9-2高甲基化水平可能与喉癌发生的病理机制有关。

Objective To assess the methylation level of MicroRNA- 129-2 （MiR- 129-2 ） in laryngeal cancer. Methods We applied Methyl-ProfilerTM DNA PCR Array System （ SABiosciences Company ） to analysis of 12 laryngeal cancer and 6 paracancer tissues. Results Hypermethylation was detected in 66. 7 % of the cancer tissue （ 8 / 12 ） and none in paracancer tissue （ 0 / 6 ） （ P 〈 0. 05 ） ; the difference was significant. Among the clinical cancer tissue of each clinical stage , there was no significant difference of MiR-129-2 hypermethylation rate （ P 〉 0. 05 ） . There was no significant difference of MiR- 129 - 2 hypermethylation rate between two pathologic grades （ P 〉 0.05 ）. Conclusion The methylation level of MiR- 129 - 2 is higher in laryngeal cancer tissue than in paracancer tissue, indicating that it may play a role in laryngeal cancer. The methylation level of MiR-129-2 may not be related with the clinical stage of laryngeal cancer. The methylation level of MiR： 129-2 may not be related with the pathologic grade of laryngeal cancer.